Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.

Background: Parenteral iron therapy is required in a majority of chronic dialysis patients who are receiving recombinant human erythropoietin (r-HuEPO) in order to provide adequate